Pathologic Response After Neoadjuvant Chemoimmunotherapy in Head and Neck Squamous Cell Carcinoma

Дата публикации: 13-08-2026 00:00:00

This cohort study compares rates of pathologic response between neoadjuvant immunotherapy and neoadjuvant chemoimmunotherapy in patients with resectable locally advanced head and neck squamous cell carcinoma in a clinical setting.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression	0	15.58	01-07-2026
2	Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC	0	5	30-06-2026
3	No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection	0	5	22-06-2026
4	Benefit of Adjuvant Chemotherapy in Patients with ctDNA-positive Resected Stage II Colon Cancer	0	14.76	30-07-2026
5	Neoadjuvant camrelizumab plus chemotherapy versus chemotherapy alone for resectable esophageal squamous cell carcinoma: A Prospective Multicenter randomised controlled study	0	13.06	19-08-2026
6	Treatment Dependent Response Modeling Using Morphologic and Qualitative Features from Perfusion and Contrast-Enhanced Susceptibility Imaging in Undifferentiated Pleomorphic Sarcoma: A Comparison of Radiation Alone Versus Consecutive Chemotherapy and Radiation	0	13.58	07-08-2026
7	Early  radiologic  response  after  two  cycles  of  neoadjuvant   chemoimmunotherapy  and pathologic  outcomes  in  resectable  non-small  cell  lung  cancer: A multicenter retrospective study	0	17.14	19-08-2026
8	Superselective intra-arterial cisplatin infusion and concomitant radiotherapy (RADPLAT) for maxillary sinus squamous cell carcinoma: an institutional experience of 118 cases	0	20.34	10-08-2026
9	Achievement of Pathological Complete Response with Neoadjuvant Ensartinib in a Patient with Locally Advanced ALK-Rearranged Lung Squamous Cell Carcinoma: A Case Report and Literature Review	0	5	16-07-2026
10	Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response	0	37.27	03-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 4.44. Источник: www.jamanetwork.com.